Compare Novartis AG (NVS) vs Raytheon Technologies Corp (RTX) Price & Performance

Novartis AGTrade

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Raytheon Technologies Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Raytheon Technologies Corp trades at $193.8 (market cap $261.85B). The key difference: Novartis AG and Raytheon Technologies Corp are close in size by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	RTX
Market Cap	$290.25B	$261.85B
Sector	Health	Industrials
52-Week High	$168.62	$212.16
52-Week Low	$113.50	$149.17
Enterprise Value	$330.27B	$293.97B
Dividend Yield	3.17%	1.5%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

Raytheon Technologies Corp

RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.

The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

RTX

OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 8 hours agoNeutral Collins Aerospace and Etihad Engineering form JV to expand aircraft MRO services in Abu Dhabi.PRNewsWire · 9 hours agoBullish Tigerair Taiwan orders 15 Airbus A321neos with fuel-efficient Pratt & Whitney GTF engines.PRNewsWire · 9 hours agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.